AbbVie's Skyrizi gains pediatric psoriatic disease indication
Seeking Alpha ·
The US FDA has approved AbbVie's Skyrizi (risankizumab) for use in children six years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Approval was based on results from the phase 3 OptIMMize psoriasis clinical trial program. A 55 mg pre-filled syringe has also been approved for patients weighing less than 40 kg. AbbVie Inc. (ABBV) Apogee Therapeutics, Inc. - M&A Call - Slideshow Apogee: 'Hold' On AbbVie $10.9B Buyout And Extended Half-Life IL-13 Zumilokibart For AD Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms Record-setting healthcare M&A activity to extend through H2: PwC
DYAX Investor Sentiment
Bullish (Long) 47% · Bearish (Short) 53%
552 participants
Related News
- OpenAI Is Building Its Own AI Chip With Broadcom. Should Nvidia Investors Be Worried?
- Market Chatter: Meta Could Explore Partnerships With Polymarket, Kalshi for New Prediction Market App
- Why Xanadu Quantum Technologies Stock Slipped 10% This Week
- Why Kymera Therapeutics Stock Popped This Week
- Why Microsoft Stock Rose Today
- Where Will XRP Be in 3 Years?